Back

Residual cholesterol and inflammatory risk in statin-treated patients undergoing percutaneous coronary intervention: proportional hazards assumption in context

European Heart Journal

3 June 2026
Organised by: Logo
Read full article
ESC Journals Interventional Cardiology

Contributors

Samantha Sartori
Samantha Sartori

Author

Kenneth F Smith
Kenneth F Smith

Author

Roxana Mehran
Roxana Mehran

Author

Icahn School of Medicine at Mount Sinai New York City , United States of America

You may be interested in
thumbnail
Congress Presentation
Inflammation and cholesterol associated residual cardiovascular risk and its dependence on chronic kidney disease in statin treated patients with coronary artery disease
30 August 2024
thumbnail
Congress Presentation
Does early initiation of non-statin therapy, evolocumab with LDL-C <50mg/dL contribute to the reduction of hospital readmissions in patients with ACS?: a single center real world evidence from ELAINE
4 April 2025
thumbnail
Congress Presentation
Risk factors control, remnant cholesterol, recurrent events and risk in patients with coronary heart disease. Our experiences
4 April 2025
thumbnail
Congress Presentation
Prognostic impact of elevated baseline CRP levels in primary PCI-treated patients with residual cholesterol risk
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources